Condition: Non-Small Cell Lung Cancer · Sponsor: Shanghai Pulmonary Hospital, Shanghai, China
This study is a prospective, single-arm, phase 2 clinical trial assessing the feasibility, efficacy, and safety of the PD-L1 inhibitor Benmelstobart (TQB2450) as an adjuvant therapy regimen in patients with pathologic stage IB, IASLC grade 3 invasive lung adenocarcinoma without EGFR active mutations or ALK rearrangement.
This description comes directly from the study's public registry record.
Haoran E, MD · +86-021-65115006 · ehr@tongji.edu.cn
Deping Zhao, MD, PhD · +86-021-65115006 · dpzhao@tongji.edu.cn
Always discuss trial participation with your own doctor first.
| Shanghai Pulmonary Hospital | Shanghai, Shanghai Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06528847